Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda Launches Japan PI/II Trial of Novavax COVID-19 Vaccine
February 25, 2021
- Japan Pharma Market Shrinks 2.4% on COVID-19, Price Cuts: IQVIA
February 24, 2021
- Taiho’s HSP90 Inhibitor Extends PFS in GIST
February 24, 2021
- Lusefi’s OD Film Version Filed in Japan: Taisho
February 24, 2021
- Astellas’ Hot Flash Drug Hits Primary Goals in PIII Studies
February 22, 2021
- Astellas/Seagen Seek Padcev’s Full Approval, Label Expansion in US
February 22, 2021
- Chugai to Develop Atea’s COVID-19 Drug AT-527 in Japan
February 22, 2021
- Japan-Bound Flights for COVID-19 Vaccines Get Underway: Pfizer, DHL, ANA
February 22, 2021
- Mitsubishi Tanabe, Keio University Tie Up for Research of Neutralizing Antibodies for COVID-19
February 22, 2021
- Ono Sets Up Investigation Panel on Bribery Issue
February 19, 2021
- Kyowa Kirin’s Novel Antibody Hits Primary Goal in Global PII for Atopic Dermatitis
February 19, 2021
- Ono Files Opdivo for Adjuvant Therapy for Esophageal Cancer in Japan
February 19, 2021
- Chugai Re-Files Patent Suit over Edirol, Now Focuses on Crystalline Form
February 18, 2021
- Mitsubishi Tanabe Accelerating Drug Discovery via Open Innovation, Early-Stage Data Sharing
February 18, 2021
- Novo Training Its Sights on Oral Diabetes Market with Rybelsus, Not Switches from GLP-1 Injectables
February 17, 2021
- FoundationOne Approved as a CDx for Pemigatinib: Chugai
February 17, 2021
- Shionogi Pharma Set to Expand CDMO Biz with Continuous Manufacturing, Eyes 10 Billion Yen Sales in FY2024
February 17, 2021
- Stella Pharma Recalls Cancer Radiation Therapy over Flawed Testing at Kyowa CritiCare
February 17, 2021
- BMS Joins Hands with Tokyo Medical and Dental University on Fibrosis Research
February 17, 2021
- Japan’s 1st Humira Biosimilar Hits Market
February 16, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…